MTVA — MetaVia Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1638287 ·
Last close
$1.25
Market Cap
$8.24M
52W High
$13.42
52W Low
$0.97
ADV30
150,963
Next earnings
—
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -4,693,000 -4,623,000 9,554,000 8,778,000 7,143,000
Jun 2026 0 — -5,385,000 -5,316,000 13,271,000 12,634,000 6,449,000
Mar 2026 0 — -4,025,000 -3,823,000 14,388,000 13,731,000 5,315,000
Dec 2025 0 — -2,046,000 -1,930,000 11,123,000 10,278,000 5,790,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,835,000
Investing CF
$-2,000
Financing CF
$10,880,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.10
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-157,969,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-14,931,000
Pretax Income TTM
$-14,446,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -13,708,000 -12,973,000 11,123,000 5,790,000 5,333,000 -15,701,000
Dec 2024 0 -28,809,000 -27,592,000 16,260,000 8,329,000 7,931,000 -24,710,000
Dec 2023 0 -15,886,000 -12,470,000 22,781,000 6,096,000 16,685,000 -10,799,000
Dec 2022 0 -11,418,000 -13,967,000 33,534,000 11,784,000 21,750,000 -11,712,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$-4,022,000
NetIncome TTM
$-14,446,000
OpCashFlow TTM
—
Assets (Latest)
$13,271,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
KYNB KYNTRA BIO, INC. $8.26M $2.04 —
AEMD AETHLON MEDICAL INC $8.17M $5.08 —
VTGN Vistagen Therapeutics, Inc. $8.34M $0.19 —
CALC CalciMedica, Inc. $8.41M $1.22 —
DARE Dare Bioscience, Inc. $8.44M $0.43 —

News headlines (Yahoo Finance, 1h cache)

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
2026-11-17 13:31 · Yahoo
MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026
2026-11-16 13:31 · Yahoo
MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-13 13:31 · Yahoo
MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial
2026-11-12 13:31 · Yahoo
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026
2026-11-09 13:31 · Yahoo
MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data
2026-11-05 13:55 · Yahoo
MTVA: 68% Liver Fat Reduction in Phase 1 Part 3B Trial of DA-1726; Plans Shift Toward MetALD and ALD Development
2026-11-05 12:00 · Yahoo
MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
2026-10-28 12:31 · Yahoo
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
2026-10-13 12:31 · Yahoo
MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
2026-09-10 12:25 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.